AR089134A1 - Arilos y heteroarilos biciclicos inhibidores de los canales de sodio - Google Patents

Arilos y heteroarilos biciclicos inhibidores de los canales de sodio

Info

Publication number
AR089134A1
AR089134A1 ARP120104629A AR089134A1 AR 089134 A1 AR089134 A1 AR 089134A1 AR P120104629 A ARP120104629 A AR P120104629A AR 089134 A1 AR089134 A1 AR 089134A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
crere
heteroaryl
nrbrb
Prior art date
Application number
Other languages
English (en)
Inventor
E Marx Isaac
Bregman Howard
R Coats James
F Dimauro Erin
Dineen Thomas
Du Bingfan
Graceffa Russell
Kreiman Charles
La Daniel
Chakka Nagasree
Anne Peterson Emily
Weiss Matthew
W Copeland Katrina
L Deak Holly
Boezio Alessandro
Boezio Christiane
Nho Nguyen Hanh
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR089134A1 publication Critical patent/AR089134A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Los compuestos son útiles para el tratamiento de enfermedades que pueden tratarse mediante la inhibición de canales de sodio tal como trastornos del dolor. También se dan a conocer composiciones farmacéuticas que contienen compuestos de la presente. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde: X¹ es CRᵃ o N; X² es CRᵃ o N; X³ es CRᵃ o N; X⁴ es CRᵈ o N; X⁵ es CRᵈ o N; X⁶ es CRᵈ o N; cada Rᵃ es de manera independiente hidrógeno, halo, -OH, NRᵇRᵇ, -alquilo C₁₋₆, -O-alquilo C₁₋₆, -haloalquilo C₁₋₆, -O-haloalquilo C₁₋₆ o -CN; R¹ es -CN, -N(Rᵉ)(CRᵉRᵉ)ₘA, -(C=O)N(Rᵉ)(CRᵉRᵉ)ₘCF₃, -C(=O)A, -O(CRᵉRᵉ)ₘA, O(CRᵉRᵉ)ₘOA, -(C=O)alquilo C₁₋₆ o un grupo arilo o heteroarilo de 5 a 10 miembros, o un grupo cicloalquilo o heterocicloalquilo de 3 a 10 miembros, donde el grupo heteroarilo o heterocicloalquilo puede poseer de 1 a 3 heteroátomos seleccionados de manera independiente a partir del conjunto que consiste en O, N o S, o un átomo de carbono en el grupo cicloalquilo o heterocicloalquilo puede ser parte de un grupo C=O, y el grupo arilo, heteroarilo, cicloalquilo o heterocicloalquilo puede ser no sustituido o sustituido con de 1 a 4 sustituyentes seleccionados de manera independiente a partir del conjunto que consiste en halo, -NRᵇRᵇ, -alquilo C₁₋₆, -O-alquilo C₁₋₆, -O-alquilo C₁₋₆CF₃, -O-alquilo C₁₋₆CN, A, -alquilo C₁₋₆Oalquilo C₁₋₆, -(SO₂)alquilo C₁₋₆, -(SO₂)NRᵇRᵇ, hidroxialquilo C₁₋₆, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -(CRᵉRᵉ)ₘCN, C(=O)NRᵇRᵇ, C(=O)ORᵇ, -(CRᵉRᵉ)ₘA, -N(Rᵉ)(CRᵉRᵉ)ₘA, -(C=N)O-alquilo C₁₋₆, -(C=O)N(Rᵉ)(CRᵉRᵉ)ₘA, -(C=O)N(Rᵉ)(CRᵉRᵉ)ₘCF₃, -O(CRᵉRᵉ)ₘA, -O(CRᵉRᵉ)ₘOA o -C(=O)A; A es un grupo arilo, heteroarilo o heterocicloalquilo de 4 a 9 miembros, donde el grupo heteroarilo o heterocicloalquilo puede poseer de 1 a 3 heteroátomos seleccionados de manera independiente a partir del conjunto que consiste en O, N o S, o un grupo cicloalquilo de 3 a 6 miembros, y el grupo arilo, heteroarilo, heterocicloalquilo o cicloalquilo puede ser no sustituido o sustituido con de 1 a 4 sustituyentes seleccionados de manera independiente a partir del conjunto que consiste en halo, -NRᵇRᵇ, -alquilo C₁₋₆ -O-alquilo C₁₋₆, -(CRᵉRᵉ)ₘOH, hidroxialquilo C₁₋₆, -CF₃, -CHF₂, -CH₂F, -OCF₃, -CN, -C(=O)NRᵇRᵇ, -O(CRᵉRᵉ)ₘB o -(CRᵉRᵉ)ₘB; B es un grupo arilo, heteroarilo o heterocicloalquilo de 5 a 6 miembros, donde el grupo heteroarilo o heterocicloalquilo puede poseer de 1 a 3 heteroátomos seleccionados de manera independiente a partir del conjunto que consiste en O, N o S, o un grupo cicloalquilo de 3 a 5 miembros, y el grupo arilo, heteroarilo, cicloalquilo o heterocicloalquilo puede ser no sustituido o sustituido con de 1 a 4 sustituyentes seleccionados de manera independiente a partir del conjunto que consiste en halo, -NRᵇRᵇ, -alquilo C₁₋₆, -O-alquilo C₁₋₆, hidroxialquilo C₁₋₆, -CF₃, -CHF₂, -CH₂F, -OCF₃, -CN o -C(=O)NRᵇRᵇ; R² es -(C=O)alquilo C₁₋₆, -(C=O)haloalquilo C₁₋₆ o un grupo arilo o heteroarilo de 5 a 10 miembros, o un grupo cicloalquilo o heterocicloalquilo de 3 a 10 miembros, donde el grupo heteroarilo o heterocicloalquilo puede poseer de 1 a 3 heteroátomos seleccionados de manera independiente a partir del conjunto que consiste en O, N o S, o un átomo de carbono en el grupo cicloalquilo o heterocicloalquilo puede ser parte de un grupo C=O, y el grupo arilo, heteroarilo, cicloalquilo o heterocicloalquilo puede ser no sustituido o sustituido con de 1 a 4 sustituyentes seleccionados de manera independiente a partir del conjunto que consiste en halo, -NRᵇRᵇ, -alquilo C₁₋₆, -O-alquilo C₁₋₆, hidroxialquilo C₁₋₆, -(CRᶜRᶜ)ₙNRᵇRᵇ, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, -CN o -C(=O)NRᵇRᵇ; cada n es de manera independiente 0, 1, 2, 3 ó 4; cada m es de manera independiente 0, 1, 2, 3 ó 4; cada Rᵇ es de manera independiente hidrógeno o alquilo C₁₋₆; cada Rᶜ es de manera independiente hidrógeno o -alquilo C₁₋₆; cada Rᵈ es de manera independiente hidrógeno, halo, -CN, -NRᶜRᶜ, -OH, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -O-haloalquilo C₁₋₆ o -O-alquilo C₁₋₆; y cada Rᵉ es de manera independiente hidrógeno, halo, -CN, NRᶜRᶜ, -OH, -alquilo C₁₋₆, -O-alquilo C₁₋₆ o un grupo heterocicloalquilo de 5 a 6 miembros que posee de 1 a 3 heteroátomos seleccionados de manera independiente a partir del conjunto que consiste en O, N o S; siempre y cuando el compuesto no es: 1-(4-fluoro-2-(pirimidin-5-il)fenil)-N-(tiazol-2-il)isoquinolina-6-sulfonamida; 1-(4-fluoro-2-(pirimidin-2-iloxi)fenil)-N-(tiazol-2-il)isoquinolina-6-sulfonamida; 5-metoxi-4-(2-metoxi-4-(trifluorometil)fenil)-N-(tiazol-2-il)quinolina-7-sulfonamida; 5-ciano-N-fenil-2-naftalenosufonamida; N-(3,4-dimetil-5-isoxazolil)-5-(1-piperidinil)-2-naftalenosulfonamida; o N-(3,4-dimetil-5-isoxazolil)-5-[(fenilmetil)amino]-2-naftalenosulfonamida.
ARP120104629 2011-12-07 2012-12-10 Arilos y heteroarilos biciclicos inhibidores de los canales de sodio AR089134A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567927P 2011-12-07 2011-12-07
US201261713304P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
AR089134A1 true AR089134A1 (es) 2014-07-30

Family

ID=47470185

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104629 AR089134A1 (es) 2011-12-07 2012-12-10 Arilos y heteroarilos biciclicos inhibidores de los canales de sodio

Country Status (6)

Country Link
US (1) US9012443B2 (es)
EP (1) EP2788332A1 (es)
AR (1) AR089134A1 (es)
TW (1) TW201336825A (es)
UY (1) UY34502A (es)
WO (1) WO2013086229A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2773637B1 (en) 2011-10-31 2016-06-08 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
CA2891056A1 (en) 2012-10-26 2014-05-01 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
CN105307655B (zh) 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
EP2968280A4 (en) 2013-03-14 2016-08-10 Genentech Inc SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
AU2015242219A1 (en) * 2014-03-29 2016-10-06 Lupin Limited Sulfonamide compounds as Voltage gated sodium channel modulators
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
KR102412146B1 (ko) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 소디움 채널 차단제
NZ737536A (en) 2015-05-22 2019-04-26 Genentech Inc Substituted benzamides and methods of use thereof
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
PE20181003A1 (es) * 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
NZ742069A (en) 2015-11-13 2019-08-30 Dae Woong Pharma Sodium channel blocker
CN115806550A (zh) * 2015-11-25 2023-03-17 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
CR20180322A (es) 2015-12-18 2018-08-21 Merck Sharp & Dohme Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje
EP3390392B1 (en) * 2015-12-18 2021-10-06 Amgen Inc. Alkyl dihydroquinoline sulfonamide compounds
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
CN106478627A (zh) * 2016-08-30 2017-03-08 华东师范大学 一种6,12,18‑三芳基‑5,11,17‑苯并三喹啉衍生物及其合成方法
KR20190078587A (ko) 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
CN111163775B (zh) 2017-10-02 2023-07-11 勃林格殷格翰国际有限公司 作为cdk8/cdk19抑制剂的新型[1,6]萘啶化合物和衍生物
JP2020536863A (ja) 2017-10-06 2020-12-17 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０の阻害
TW202000651A (zh) 2018-02-26 2020-01-01 美商建南德克公司 治療性組成物及其使用方法
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
MX2020012180A (es) 2018-05-17 2021-01-29 Forma Therapeutics Inc Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
CN113166108A (zh) 2018-10-05 2021-07-23 福马治疗有限公司 作为泛素特异性蛋白酶30(usp30)抑制剂的稠合吡咯啉
KR20210108367A (ko) 2018-11-09 2021-09-02 비바체 테라퓨틱스, 인크. 비시클릭 화합물
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
US11535595B2 (en) 2018-12-18 2022-12-27 D. Western Therapeutics Institute, Inc. Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof
MX2021012638A (es) 2019-04-16 2022-01-04 Vivace Therapeutics Inc Compuestos biciclicos.
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
EP4347032A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2022256708A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
KR20240031300A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds
CA3242011A1 (en) * 2021-12-23 2023-06-29 David Maloney Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023255771A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707985A (en) * 1995-06-07 1998-01-13 Tanabe Seiyaku Co. Ltd. Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators
PA8444901A1 (es) 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
WO2004103980A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
CA2607670A1 (en) 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
ZA200710332B (en) 2005-05-16 2009-03-25 Vertex Pharma Bicyclic derivatives as modulators of ion channels
CN101415691B (zh) * 2006-02-03 2011-12-14 大正制药株式会社 三唑衍生物
RS53941B1 (en) 2009-01-12 2015-08-31 Pfizer Limited SULFONAMID DERIVATIVES
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine

Also Published As

Publication number Publication date
US9012443B2 (en) 2015-04-21
TW201336825A (zh) 2013-09-16
US20130150339A1 (en) 2013-06-13
EP2788332A1 (en) 2014-10-15
WO2013086229A1 (en) 2013-06-13
UY34502A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
AR089134A1 (es) Arilos y heteroarilos biciclicos inhibidores de los canales de sodio
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
RU2460730C2 (ru) Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли
RU2013150811A (ru) Ингибиторы идо
RU2017122364A (ru) N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина
RU2018121834A (ru) Новое соединение бифенила или его соль
NZ627750A (en) Carbamate compounds and of making and using same
JP2015522036A5 (es)
CA2903288A1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
JP2015520769A5 (es)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
NZ716420A (en) Fused heterocyclic compounds as sodium channel modulators
JP2013531029A5 (es)
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
AR083872A1 (es) Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты

Legal Events

Date Code Title Description
FA Abandonment or withdrawal